Outlook for RNAi, 2007: siRNA and miRNA in Biology, Diagnostics and Therapeutics
Posted on: Tuesday, 28 August 2007, 06:13 CDT
Reportlinker.com announces that a new market research report related to the worldwide biotechnology industry is now available to its catalogue.
Outlook for RNAi, 2007: siRNA and miRNA in biology, diagnostics and therapeutics
http://www.reportlinker.com/p054680/Outlook-RNAi.html
RNAi-based screens have provided new opportunities for the discovery and validation of novel therapeutic targets in areas such as cancer and infectious diseases. Since 2005, enormous strides have also been made in the development of RNAi-based therapeutic products, bringing them significantly closer to the market.
'Outlook for RNAi 2007' is a new report which provides a detailed insight into the most effective use of this novel technology in the drug discovery and development process. It puts into context where RNAi technology is being used as a tool of choice within academia and the pharma industry for functional genomic studies, drug target discovery and mechanism of action studies. The development status RNAi based therapeutics is covered in detail, highlighting the key companies in the field, outlining their pipelines and describing the results of completed clinical trials.
Understand how RNAi technology is being used to improve drug attrition rates and develop new therapeutic agents, and ensure that you are up-to-date with developments in this advancing field.
Key findings
The RNAi market is a relatively immature with global sales of approximately $447 million in 2006. It is projected to reach $0.9 billion by 2010, a compound annual growth rate (CAGR) of 19% between 2006-2010.
One of the main reasons for RNAi's popularity stems from its utility as a molecular biology tool enabling the in vivo functional analysis of thousands of genes. Recent advances in the field include the design of new libraries of RNAi effectors, delivery systems and read-out methods.
In 2005, delivering RNAi triggers was the biggest obstacle in creating effective RNAi-based therapies. Subsequently, research into new and effective delivery methods has taken place at a frantic pace, although there are still major issues to be addressed.
The first human trials of a systemic RNAi-based therapeutic were initiated in 2007 by Quark Biotech.
In the last two years, a more thorough understanding of the mechanism of action and intracellular pathways of miRNA has developed. miRNA is now an alternative gene knock-down technology that is being applied in research and for therapeutic and diagnostic applications.
Key questions answered
What will the growth of the RNAi market be over the next 5 years?
Who are the leading players in the RNAi market?
How are big pharma companies capitalizing on this technology through strategic alliances with specialized players?
Which areas of therapeutic interest are being explored with RNAi-based agents?
What are the Intellectual Property implications of RNAi research?
What challenges must be overcome for RNAi technology to yield commercially viable therapeutics and make a substantial improvement to drug-attrition rates?
Key issues examined in this report
The value and breakdown of sub-sector performances of the RNAi market between 2006-2015.
The therapy areas, progress of clinical research, potential drug sales and patent position of companies at the forefront of RNAi-based therapeutics.
The relative strengths and weaknesses of different approaches to RNAi delivery and selectivity.
The key trends that are currently affecting the RNAi market such as the development of new reagents, availability of custom synthesized siRNA, development of RNA microarrays and their impact on the R&D process
The development of miRNA for diagnostic and therapeutic purposes.
Table of content
Executive Summary
Introduction
Design and Production of RNAi effectors
RNAi Research and Applications
Delivering RNAi therapeutics
RNAi Therapeutics: Progress and the Future
miRNA: diagnostics and therapeutics
Regulatory issues and patents
RNAi markets and trends
Chapter 1 Introduction
Summary
Introduction
DNA to RNA to protein -- a primer
Antisense technologies
RNA interference
Overview and significance
RNAi's mechanism
Post-transcriptional gene silencing (PGTS) by siRNA
miRNA pathways
Transcriptional gene silencing (TGS) by siRNA
Other non-coding RNAs
Advantages and disadvantages of RNAi
Report Outline
Chapter 2 Design and Production of RNAi effectors
Summary
Introduction
Design of RNAi effectors
siRNA design algorithms
Building silencing efficiency
Avoiding off-target effects
Chemical modification
Avoiding immunostimulation
Finding the right target sites
miRNA mimics
Production of RNAi effectors
Chemical Synthesis
siRNA pools
Dicer-substrate siRNAs (DsiRNAs)
Expression vectors
Plasmid expression vectors
Expression from a PCR product
Viral expression vectors
Conclusions
Chapter 3 RNAi Research and Applications
Summary
Introduction
Elucidating gene function
High throughput loss-of-function screening with RNAi
Choice of species and cell-line
RNAi reagents
Delivery method
Screening paradigm and format
Read-out methods
Building pathways
Investigating gene function in vivo
Applications of RNAi in drug discovery and development
Target discovery and validation
Optimization of drug therapy and development of personalized medicine
miRNA Research
miRNA Databases and Algorithms
Identifying miRNAs, their targets and function
Isolation and enrichment of miRNA
Detection and quantification of miRNA
Functional analysis
Conclusions
Chapter 4 Delivering RNAi therapeutics
Summary
Introduction
Direct organ delivery
Stabilization of siRNAs
Non-viral delivery methods
Cholesterol and peptide conjugation
Liposomal delivery
Conjugation with cell penetrating peptides
Atelocollagen
Targeted polymeric delivery
Aptamer-siRNA complexes
FAb-siRNA complexes
MAb-siRNA complexes
Targeted nanoparticle delivery methods
Targeting with transferrin
Targeting with apatmers
Targeting with RGD peptide
Delivering RNAi via Plasmid DNA
Virosomes
Viral delivery methods
Conclusions
Chapter 5 RNAi Therapeutics: Progress and the Future
Summary
Introduction
siRNA Therapeutics: Analysis by Therapeutic Area
Ocular Diseases
Age-related Macular Degeneration (AMD)
Key RNAi players
Diabetic Retinopathy
Viral diseases
Respiratory Syncytial Virus (RSV)
Key RNAi Players
HIV
Key RNAi players
Hepatitis C Virus (HCV)
Key RNAi players
Hepatitis B Virus (HBV)
Key RNAi players
Pandemic Flu
Key RNAi players
SARS
Key RNAi players
Herpes Simplex Virus (HSV)
Other viral diseases
Respiratory diseases
Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Key RNAi Players
Cystic fibrosis (CF)
Key RNAi players
Neurological diseases
Oncology
Angiogenesis
Key RNAi players
Oncogenes
Key RNAi players
Cardiovascular disease
Key RNAi players
Metabolic disorders
Diabetes and Obesity
Key RNAi players
Dermatology
Hair Removal
Key RNAi players
Pachyonychia congenita and related disorders
Key RNAi Players
Acute renal failure
Key RNAi players
Acute hearing loss/ pressure sores ototoxicity
Key RNAi players
Inflammatory Diseases
Key RNAi players
Conclusions
Chapter 6 miRNA: diagnostics and therapeutics
Summary
Introduction
miRNA as a diagnostic tool
Companies developing miRNA-based diagnostics
Rosetta Genomics
Cepheid
Stratagene
miRNA-based therapeutics
Companies developing miRNA-based therapeutics
Alnylam Pharmaceuticals
Asuragen Inc
Santaris
Sirna
Conclusions
Chapter 7 Regulatory issues and patents
Summary
Introduction
Patents in RNAi
Seminal patents in RNAi
Alnylam
Sirna
Chemical modifications
DNA directed RNAi
Patents for specific RNAi targets
The future -- more patent litigation?
MicroRNA
Tuschl III patents
Zamore and other patents
Regulatory considerations for RNAi therapies
Conclusions
Chapter 8 RNAi markets and trends
Summary
Introduction
The RNAi market
Market size and future trends
RNAi suppliers: synthesis and reagents
Alliances with big pharma for RNAi in R&D
Delivery of RNAi therapeutics
RNAi-based therapeutics
Big pharma alliances for RNAi-based therapeutics
miRNA-based diagnostics
Conclusion
More market research reports? Go to http://www.reportlinker.com
http://www.reportlinker.com/Rss/en01234/biotech-free-market-resear ch-reports.xml
http://www.reportlinker.com/Rss/en01237/biotechnology-free-market- research-reports.xml
http://www.reportlinker.com/Rss/en012605/biotechnology-instrumenta tion-free-market-research-reports.xml
http://www.reportlinker.com/Rss/en015656/biotechnology-patent-free -market-research-reports.xml
http://www.reportlinker.com/Rss/en012624/biotechnology-patents-fre e-market-research-reports.xml
http://www.reportlinker.com/Rss/en012615/biotech-drug-discovery-pr ocess-free-market-research-reports.xml
(Due to their length, these URLs may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists)
Source: Business Wire
Related Articles
- Key Player In Cascade That Leads To Hypertension-Related Kidney Damage
- Key Statistics Telecom Market & Regulatory Overviews of the United Kingdom Market
- China Potassium Sulfate Market Study Research Report Provides Estimations and Analysis on China's Potassium Sulfate Market for 2007-2008
- Market Advisors Research Issues Report on Toro Ventures With an Intermediate Term Range of $2.80 Per Share
- Study Shows Intradigm's RNAi Nanoplex Technology To Be Effective Systemic siRNA Delivery Platform for the Treatment of Various Cancer Models
- France - Key Statistics, Telecom Market & Regulatory Overviews Now Available
- Study the Key Players in Rheumatoid Arthritis Research & Development With This New Clinical Trial Monitoring Brief Today
- Code Green Networks Named 'Key Player' and 'Security Vendor to Watch' By CRN Magazine
- NEC Computers Aims to Be Key Player in PC Mart
- Local Companies Key Players in Hitting a Triple
 |
 |
User Comments (0)
RSS Feeds